Treatment News : Cardiovascular Disease Risk Remains High in HIV Elite Controllers

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » October 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


October 4, 2012

Cardiovascular Disease Risk Remains High in HIV Elite Controllers

More evidence that immune activation and inflammation are key drivers of the increased cardiovascular disease risk among people living with HIV: Elite controllers—a rare subset of HIV-positive individuals who maintain undetectable viral loads and high CD4 cell counts in the absence of antiretroviral therapy—have significant plaque hardening of the arteries (atherosclerosis), according to the results of a study published online ahead of print by the journal AIDS.

“We demonstrate an unexpectedly high degree of coronary atherosclerosis and elevated markers of immune activation in [elite controllers],” the Harvard University-affiliated researchers wrote. “Interestingly, the degree of atherosclerosis was similar, if not greater, compared to [people living with HIV] receiving long-term [antiretroviral therapy] with suppressed viremia.”

The study enrolled 10 HIV elite controllers, 103 people living with HIV with undetectable viral loads while receiving antiretroviral therapy and 49 HIV-negative individuals.

The prevalence of arterial plaques was 78 percent among the elite controllers, compared with 42 percent of the HIV-negative study volunteers.  Among those with HIV infection receiving treatment, the prevalence was 60 percent.

The researchers conclude that the “precise interplay” between immune activation, the highly effective HIV-specific T-cell responses that differentiate many of those with elite control of the virus and those with chronic infection, low-level HIV replication and cardiovascular disease “need to be fully elucidated in larger studies” of elite controllers.

To read the AIDS report, click here (paid subscription required).

Search: hiv, elite controllers, long-term nonprogressors, inflammation, immune activation, cardiovascular disease, cvd, atherosclerosis

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.